Hans-Peter Gerber, Ph.D.

Hans-Peter Gerber, Ph.D.

Chief Scientific OfficeratSutro Biopharma· In proxies 2023–2025

Pay in FY2025-18% from the year before · Sutro Biopharma stock -37.1% the same year

Hans-Peter Gerber, Ph.D. was paid $942.9K in FY2025 (Dec), down 18%. Sutro Biopharma stock fell 37.1% that year.

Pay$100 in the stock at the end of FY22 → $14
Pay is from the Summary Compensation Table of each Sutro Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Sutro BiopharmaPublic company · 3 yr
    • Chief Scientific Officer2023 – Present · 3 yrStock in role -86%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?